MXCT vs NSC · rev $38.6M vs P/E 18, rev $12.12B
MaxCyte Inc (MXCT) versus Norfolk Southern Corporation (NSC) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported NSC revenue for 2024-12-31 was $12.12B. Net income was $2.62B. Revenue was down 0.3% from 2023-12-31 to 2024-12-31. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
MXCT currently screens at market cap $124.3M. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Not investment advice. Open the MXCT and NSC stock pages for the full models.
Not investment advice.